°w¹ï§Z±_¦°IijÃD¡A¼Ú¬w¥Í´ÞÂå¾Ç·|Âǥѷj´M¸ê®Æ®w(¥]§tPUBMED/MEDLINE, Cochrane library, Psyclnfo)¤º¬ÛÃö¤º®e¡A¾ã²zÀÀ©w¦¹Á{§É«ü¤Þ¡A¨ÑÁ{§ÉÂå®v°Ñ¦Ò¡A¹wp¥|¦~«á¦A×q¡C¨ä¥Dn¤º®eºKn¦p¤U:
§Z±_¦°I©w¸q©MÁ{§Éªí²{:
§Z±_¦°Iªº¶EÂ_º¥ý¦b1942¦~³Q´£¥X¡A¥Ø«eÁ{§É±M®a¦@ÃѥΔprimary ovarian insufficiency”(²ºÙPOI)³oÓ¦Wµü¨ÓÄÄz¡C¨ä©w¸q¬°¡A¦b40·³«e³à¥¢§Z±_¥\¯à(loss of ovarian activity before the age of 40 years)¡CÁ{§Éªí²{¥]§t¤ë¸g¥¢½Õ(µL¤ë¸g©Î¤ë¸g¹L¤Ö)¡A¦P®É¦ñÀH¦å²G¤¤gonadotropin¿@«×¤É°ª¥B»Û¿E¯À¿@«×§C¡C¥Ø«eµo¥Í²v¬ù¬°1%¡A¤£¦PºØ±Ú¡Aµo¥Í²v¤£¦P¡C
¦p¦ó¶EÂ_§Z±_¦°I:
ÁöµM½T¤Á¶EÂ_POIªº¼Ð·Ç¯Ê¥F¡A¦ý¥Ø«e±M®a¦@ÃѶEÂ_¼Ð·Ç¦p¤U¡A(1)µL¤ë¸g©Î¤ë¸g¹L¤Ö¦Ü¤Ö4Ó¤ë¡A(2)¨â¦¸(¶¡¹j¥|©P¥H¤W)¦å²G¤¤FSH¿@«×¤j©ó25IU/I¡CÁ{§É¤W¡A¤p©ó40·³Y¦³¤ë¸g¥¢½Õ©Î»Û¿E¯À¯Ê¥F¯gª¬¡AÀ³¶i¤@¨BÀˬd±Æ°£POI¶EÂ_¡C
³y¦¨§Z±_¦°Iì¦]«Ü¦h¡A¥i¨Æ¥ý¹w´úªº¦MÀI¦]¤l¥]§t:(1)°ü¬ì§Z±_¤â³N¡A(2)¥Í¬¡«¬ºA¡A¥Dn¬°§lµÒ¡A(3)¯e¯f©Ò»Ý¤§¤Æ¾ÇªvÀø¡B©ñ®g½uªvÀø¡C¦p«D¤Wz±¡ªp¡A¦bªì¨B¶EÂ_¬°POI«á¡A»Ýn¶i¤@¨B¤ÀªRPOIªºì¦]¡A«ØijÀˬd¶µ¥Ø¦p¤U:
Àˬd¶µ¥Ø Á{§ÉÀ³¥Î
¬V¦âÅé/°ò¦]¤ÀªR
¬V¦âÅé¤ÀªR ©Ò¦³«DÂåì©Ê¾ÉPªºPOI³£À³¸Ó°µ¬V¦âÅéÀˬd¡A³Ì±`¨£²§±`¬°Turner syndrome¡AYµo²{Y chromosome¦¨¤À¡A«Øij§Z±_¤Á°£
Fragile X premutation test POI¯f¤H·í¤¤¦³12~28%¬°fragile X premutation carrier¡A«Øij©Ò¦³¥¼©úì¦]POI¯f¤H·í§@±`³WÀˬd
Autosomal genetic testing ÃhºÃ¦³¯S©w°ò¦]¬ðÅܪ̥i°µ
§ÜÅéÀˬd Àˬd®É¾÷¬°POIì¦]¥¼©ú©ÎÃhºÃ©M§K¬Ì¯e¯f¬ÛÃö
21OH-Ab/adrenocortical antibodies(ACA) Y§e¶§©Ê¡AÂश¦Ü¤º¤Àªc¬ìµû¦ôµÇ¤W¸¢¥\¯à¤Î¯e¯fY§e³±©Ê¡A©¹«á°£«D¦³Á{§É¯gª¬¡A§_«h¤£»Ý«½Æ¿zÀËTPO-Ab Y§e¶§©Ê¡A«Øij¨C¦~°lÂÜTSH
¥Ø«e¤´¦³75~90%¯f¤H¬°¤£©úì¦]POI¡C¿}§¿¯f©M·P¬V¿zÀˤ£»Ý±`³WÀËÅç¡AY¯f¤H¥i¯à¦]¬°¤º¡B¥~¬ìªvÀø¦Ó¾ÉPPOI¡A¦bªvÀø«en¥ý¹ï¯f¤H°µ§¹¾ã¿Ô¸ß¡A¦Ó§lµÒÁöµM¨S¦³¨¬°÷ÃÒ¾Ú¤ä«ù©MPOI¦³¦]ªGÃö«Y¡A¦ý¥i¯à³y¦¨´£¦°±¸g¡A©Ò¥H¦³POI·ÀI¯f¤H«Øij§ÙµÒ¡C
¥t¥~¡A°w¹ïfragile X premutation carrierªº¤k©Ê¿ËÄÝ¡A¬ÒÀ³´£¨Ñfragile X premutation test¥B°w¹ï¥H¤UijÃD°µ¿Ô¸ß: (1)Y¥»¨¤]¬O±aìªÌ¡A¤é«áPOIªº·ÀI°ª¡A¥Ø«e¨ÃµL¥i¥H·Ç½T¹w´úPOIªº¤è¦¡¡A¤]¨S¦³¹w¨¾POIªºªvÀø¡A(2)¦]À³¥i¯àPOI©Î´£¦°±¸g¡A«·s«ä¦Ò®a®xpµe¥H¤Î¥Í¨|«O¦s¬O§_¥²n¡C
§Z±_¦°Iªº¼vÅT:
¾ãÅé¦Ó¨¥¡A¥¼ªvÀøªºPOI©M¥§¡¹Ø©R´î¤Ö¦³Ãö¡A¥Dn¬°¤ß¦åºÞ¯e¯f¾ÉP¡A¦]¦¹POIªº¯f¤H³£À³¸ÓÁקK§lµÒ¡B³W«ß¹B°Ê¤Îºû«ù¾A·íÅ髨Ӱ§C·ÀI¡C¨ä¥L¦U¤è±¼vÅT¦p¤U:
1. ¥Í¨|ªº¦Ò¶q:©Ò¦³POI¯f¤H¬ÒÀ³§iª¾¨ä¦ÛµMÃh¥¥¾÷²v«Ü§C¡A¦ýYpµe¤£Ãh¥¥¡A¤´¶·±Ä¨úÁ×¥¥±¹¬I¡C¥Ø«e¨S¦³³QÃҹ꦳®Ä´£¤É§Z±_¥\¯à¤Î¦ÛµMÃh¥¥ªº¤è¦¡¡A¹ï·QÃh¥¥ªº¯f¤H¡A±µ¨ü§Z¤l®½ÃجO¥i¦æªº°µªk¡C
2. Ãh¥¥ªº·ÀI:Y¯f¤H¬°¦ÛµMÃh¥¥¡A¨äÃh¥¥·ÀI¤£·|¤ñ¤@¯ë¤H°ª¡CY±µ¨ü§Z¤l®½ÃØÃh¥¥¡Aµø¬°°ª¦MÀI§³®W¡C²£«e¬V¦âÅéÀˬd¬O§_»Ýn°õ¦æ¡Aµø§Z¤l®½Ãت̪º¦~¬ö¦Ó©w¡CY¤l®c¤§«e¦³±µ¨ü¹L©ñ®g½u¼ÉÅS¡A²£¬ì¨Öµo¯g¾÷·|´£°ª¡A«Øij¦b¾A·íªºÂå°|±µ¨ü·ÓÅ@¡CTurner syndromeªº¯f¤HÃh¥¥·ÀI·¥°ª¡A¥]§t¤ßŦ¤è±°ÝÃD¡A¦]¦¹¡AÃh¥¥®É»Ýn²£¬ì¤Î¤ßŦ¬ìÂå®v¦@¦P·ÓÅ@¡C
©Ò¦³¦]POI¦³·NÄ@±µ¨ü§Z¤l®½Ãت̡A¨üÃØ«e¬Ò»Ý°µ¥þ±¨ÅéÀˬd¡A¥]¬A¦åÀ£¡BµÇ¥\¯à¡B¥Òª¬¸¢¥\¯à¡BµÇ¤W¸¢¥\¯à¤Î¬V¦âÅéÀˬd¡A½T«O¨ä°·±dª¬ºA¾A¦XÃh¥¥¡CY¯f¤H¥ý«e¦³±µ¨ü°ª¾¯¶qcyclophophamide¡AÁa»JµÄ©ñ®g½uªvÀø¡A©Î¬°Turner syndrome¯f¤H¡A»Ýn¥Ñ¤ßŦ¬ìÂå®vµû¦ô¨ä¤ßŦ¥\¯à¬O§_¥i©Ó¨üÃh¥¥¡Cºî¦X¤WzÀˬdµ²ªG¡AY¯f¤HÃh¥¥·ÀI·¥°ª¡AÁ{§ÉÂå®v»Ý§iª¾¨ä¤£¾A¦XÃh¥¥¡C
3. °©Àfªº°·±d: POI·|¾ÉP°©±K«×°§C¡AÀH¤§°©§é¾÷·|´£°ª¡C§ïµ½°©Àf°·±d¤è¦¡¥]§t:(1)°·±d¥Í¬¡«¬ºA: ¾A«×¹B°Ê¡BÁקK§lµÒ¡Bºû«ù°·±dÅé«¡A§¡¿Å¶¼¹¡Aª`·N¶t©Mºû¥Í¯ÀDªº¸É¥R¡A(2)»Û¿E¯À¸É¥R: ¥i¥H¹w¨¾°©½è²¨ÃP¡B°§C°©§é·ÀI¡C¶EÂ_POIªº¦P®É¥i¥H°µ°©±K«×´ú¶q¡A§@¬°¤é«áªvÀøµû¦ô¨Ì¾Ú¡C
4. ¤ß¦åºÞ¨t²Îªº°·±d:©Ò¦³¯f¤H¦b¶EÂ_¦P®É¤Î©¹«á¨C¦~¡A«Øij°µ¤ß¦åºÞ¯e¯f·ÀIµû¦ô¡A¤º®e¥]§t¦åÀ£¡BÅé«¡B§lµÒ¡B¦å¿}¤ÎÁx©T¾Jµ¥¡CºÉ¦¨Ï¥Î»Û¿E¯À¹ï¯f¤H¬O¦³¯q³Bªº¡A«Øij¸É¥R¦Ü¥§¡¦ÛµM°±¸g¦~ÄÖ¡C
5. ¨ä¥L: POIªº¯f¤H¡A¦bºë¯«¼h±¤Î¥Í¬¡«~½è³£¥i¯à¦³t±ªº¼vÅT¡A»Ýn¾A®É¤¶¤J½Õ¾ã¡C¦b©Ê¥Í¬¡¤è±¡A§½³¡»Û¿E¯À©M¼í·Æ¾¯¨Ï¥Î¥i§ïµ½©Ê¥æ¯kµh¡CY¯f¤H¦³¥Í´Þªc§¿¹D¯gª¬¡A§½³¡»Û¿E¯À¥ç¥iÀ°§U§ïµ½¡C
§Z±_¦°IªºªvÀø:
ªvÀø°ò¥»¤W¥H¸É¥R¶Pº¸»X¬°¥D¡A¥i¥H§ïµ½§C»Û¿E¯À³y¦¨ªº¯gª¬¡A¹w¨¾¤ß¦åºÞ¯e¯f¡A«OÅ@°©Àf°·±d¸É¥R¡C¹ï¦³¤l®cªº¯f¤H¡A°£¤F»Û¿E¯À¥~¡A»Ý¥[¤W¶ÀÅé¯À¨Ó«OÅ@¤º½¤¯fÅÜ¡C»Û¿E¯Àªº¸É¥R¡A17-βestradiol¸û¨Î¡C¶}©l¶Pº¸»XªvÀø«á»Ý©w´Áµû¦ô¨ä®ÄªG©M°Æ§@¥Î¡C¦Ü©ó¶¯©Ê¯À(androgen)ªº¸É¥R¡Aªø´Á¼vÅT¥Ø«eµL©w½×¥B¤£«Øij¡C
ì«h¤W¨ÅÀù¬°ªvÀøªº¸T§Ò¯g¡A¦ÓBRCA°ò¦]¬ðÅܱaìªÌ¦pªG¨S¦³¨ÅÀù¯f¥v¡A¶i¦æ¹w¨¾©ÊÂù°¼§Z±_¿é§ZºÞ¤Á°£³N«á¡A¥i¦Ò¼{¨Ï¥Î¶Pº¸»XªvÀø¡C°¾ÀYµh©M°ª¦åÀ£¬Ò«DªvÀø¸T§Ò¯g¡A¦ý¿ï¾Ü¸g¥Ö½§§l¦¬ªºµ¹Ãij~®|¸û¨Î¡C¹ï©óÀR¯ß®ê¶ë°ª·ÀI¯f¤H¤ÎªÎD±wªÌ¡A¸g¥Ö½§§l¦¬ªºµ¹Ãij~®|¬O¤ñ¸û¦X¾Aªº¡C
«C¬K´Á»¤¾É:
²Ä¤@¶¥¬qªvÀø(12-13·³)©y³æ¥Î§C¾¯¶q»Û¿E¯À¡A¨C¥b¦~¦Ü¤@¦~½Õ¾ã¾¯¶q¡A¬ù¨â¦~«á¹F¨ì¦¨¤H¾¯¶q¡CY¸û±ß¶EÂ_©Î¨°ª«DªvÀøªº¦Ò¶q¡A¥i¥Î¸û°ª¾¯¶q»Û¿E¯ÀªvÀø¡A¸g¥Ö½§µ¹ÃĬO¸û¨Îªº§ëÃĤ覡¡A¤fªAÁ×¥¥ÃĤ£¾A¦X¥Î¨Ó·í§@«C¬K´Á»¤¾ÉªvÀø¡Cµ¹¤©»Û¿E¯À¨â¦~«á¡A¶·¥[¤W¶g´Á©Ê¶ÀÅé¯À¨Ï¥Î¡C
Á`µ²:
¦¹Á{§É«ü¤ÞÁöµM³\¦h«Øij³£¬O±M®a·N¨£¡A¨S¦³±j¯P¹êÃÒÂå¾ÇÃÒ¾Ú¡A¦ý¤´¨ã°Ñ¦Ò»ùÈ¡A¥i¨ÑÁ{§ÉÂå®v°Ñ¦Ò¡A©¹«á¡A°w¹ï¦UÓ¤£¦Pªº¬ÛÃöijÃD¡A´Á«Ý¦³§ó¦h¶i¤@¨Bªº¬ã¨s¡C
ƒÜ °Ñ¦Ò¤åÄm:
ESHRE Guideline: managementof women with premature ovarianinsufficiency Hum Reprod. 2016; 31(5):926-37
|